Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Ntanasis‐Stathopoulos, Ioannis; Gavriatopoulou, Maria; Terpos, Evangelos; Dimopoulos, Meletios A.

doi:10.1016/j.clml.2021.01.018

Cited by 11 publications

(9 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cardinal clinical features of MM include anemia, hypercalcemia, renal impairmentand myeloma-related bone lesions [ 2 ]. The prognosis of MM patients has significantly improved over the past 15 years, mainly due to the incorporation of novel agents.However, it still remains an incurable disease and all patients will eventually relapse [ 3 ]. MM is considered a disease of the elderly, with a median onset age of 69 years.…”

Section: Introductionmentioning

confidence: 99%

Metabolic Disorders in Multiple Myeloma

Gavriatopoulou

Paschou

Ntanasis‐Stathopoulos

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematological malignancy and is attributed to monoclonal proliferation of plasma cells in the bone marrow. Cancer cells including myeloma cells deregulate metabolic pathways to ensure proliferation, growth, survival and avoid immune surveillance, with glycolysis and glutaminolysis being the most identified procedures involved. These disorders are considered a hallmark of cancer and the alterations performed ensure that enough energy is available for rapid cell proliferation. An association between metabolic syndrome, inflammatory cytokinesand incidence of MM has been also described, while the use of metformin and statins has been identified as a positive prognostic factor for the disease course. In this review, we aim to present the metabolic disorders that occur in multiple myeloma, the potential defects on the immune system and the potential advantage of targeting the dysregulated pathways in order to enhance antitumor therapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolic Disorders in Multiple Myeloma

Gavriatopoulou

Paschou

Ntanasis‐Stathopoulos

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…While therapeutic advancements are made, MM patients continue to experience progressively shorter periods of remission followed by relapse, and their disease eventually becomes resistant to all available regimens, including PIs, IMiDs and mAbs [ 46 ]. Incorporating mAbs and new immunotherapeutics in the treatment regimen while simultaneously exploring new therapeutic modalities is critical to addressing the remaining clinical need.…”

Section: Discussionmentioning

confidence: 99%

Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world

Huang,

Zhang,

Punnoose

et al. 2023

Antibody Therapeutics

View full text Add to dashboard Cite

Multiple myeloma (MM) is a highly heterogeneous malignancy with genetically complex risk factors. The treatment of MM has been significantly advanced in recent years. B cell maturation antigen (BCMA)-targeted immunotherapy and chimeric antigen receptor T (CAR-T) cell therapy have been approved by the US Food and Drug Administration (FDA) for the treatment of relapsed and refractory MM (RRMM) since 2020. These new therapeutic modalities are promising options for curing MM, which will be launched in China shortly. The approval of the CD38 antibody, daratumumab, provided more therapeutic options for MM. Daratumumab not only improves the clinical outcomes both RRMM and newly diagnosed MM patients. Daratumumab was granted approval in 2019 by the National Medical Products Administration (NMPA) of China. The combination of daratumumab, bortezomib, and dexamethasone also achieved favorable outcomes as the first-line therapy in China. However, high-risk patients have limited benefits from these advanced therapeutics, and usually relapse early, progressing into aggressive end-stage MM. Therefore, novel therapies are sought to improve the cancer prognosis in these patients. Bispecific antibodies (BsAbs) and CAR-T cells redirect the effector immune cells to tumor cells or enhance the anticancer properties of T cells. Therapeutics targeting MM-specific antigens, such as BCMA, CD38, and Fc receptor homolog 5 (FcRH5), are presently in clinical progress with promising outcomes. Based on these results, standard treatment regimens are substituted. This review furnishes an overview of the recent clinical developments of these novel drugs and compares the drug candidates under development in China to the rest of the world.

show abstract

“…Real-world studies have a higher external validity than clinical trials, since they are deprived of the strict inclusion and exclusion criteria of the latter, and, thus, the real-world study population is more representative of clinical practice [9,10]. The robustness of clinical trial results based on strict trial design is necessary from a regulatory perspective; however, the extrapolation of clinical trial outcomes and the incorporation of the novel agents into everyday practice can be evaluated with real-world evidence [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

Ntanasis‐Stathopoulos

Malandrakis

Fotiou

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41–81) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4–10). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0–7), whereas the median PFS among the responders was 12 months (95%CI: 6–18). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2–3 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit.

show abstract

Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Cited by 11 publications

References 67 publications

Metabolic Disorders in Multiple Myeloma

Metabolic Disorders in Multiple Myeloma

Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

Contact Info

Product

Resources

About